Ananda Developments Plc finance director Jeremy Sturgess-Smith tells Proactive's Stephen Gunnion the company's graduation to the senior Apex segment of the Aquis Stock Exchange Growth Markets marks a significant milestone, reflecting its adherence to strict corporate governance rules and increased market confidence. Sturgess-Smith highlighted the company's growth, meeting criteria such as a market cap of at least £10 million and having 25% of its stock in public hands. He emphasised the importance of having two independent Non-Executive Directors, John Treacy and Professor Clive Page, who bring valuable experience and credibility. The graduation to Apex is expected to enhance visibility, liquidity, and investor confidence. Ananda is considering dual listing on other trading platforms, including the Frankfurt Stock Exchange, to tap into markets with strong medical cannabis industries, and the OTCQB in New York as a long-term strategy. Sturgess-Smith also provided updates on Ananda's two phase 2 clinical trials and the MRX1 study using mice. The company is on track to begin dosing later this year, with ongoing discussions with MHRA and ethics submissions. He invited investors to join Anand's AGM on Friday August hosted through Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register For more insightful videos, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe to our channel, and enable notifications for future content. #AnandaDevelopments #AquisApex #ClinicalTrials #MedicalCannabis #CorporateGovernance #InvestorUpdates #StockMarket #FinanceDirector #ProactiveInvestors #Phase2Trials #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews